Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Raw Materials (2021 - 2025)

Mirum Pharmaceuticals has reported Raw Materials over the past 5 years, most recently at $2.9 million for Q4 2025.

  • Quarterly results put Raw Materials at $2.9 million for Q4 2025, down 4.36% from a year ago — trailing twelve months through Dec 2025 was $2.9 million (down 4.36% YoY), and the annual figure for FY2025 was $2.9 million, down 4.36%.
  • Raw Materials for Q4 2025 was $2.9 million at Mirum Pharmaceuticals, up from $2.9 million in the prior quarter.
  • Over the last five years, Raw Materials for MIRM hit a ceiling of $3.0 million in Q4 2024 and a floor of $444000.0 in Q3 2023.
  • Median Raw Materials over the past 5 years was $2.9 million (2024), compared with a mean of $2.4 million.
  • Biggest five-year swings in Raw Materials: soared 528.38% in 2024 and later dropped 4.36% in 2025.
  • Mirum Pharmaceuticals' Raw Materials stood at $856000.0 in 2021, then rose by 0.23% to $858000.0 in 2022, then soared by 249.42% to $3.0 million in 2023, then grew by 1.07% to $3.0 million in 2024, then fell by 4.36% to $2.9 million in 2025.
  • The last three reported values for Raw Materials were $2.9 million (Q4 2025), $2.9 million (Q3 2025), and $2.9 million (Q2 2025) per Business Quant data.